Dengue is no longer a concern only for districts in eastern Chad. In October 2026, its spread to N’Djamena is confronting health services with a twofold emergency: identifying patients early enough and being able to treat severe cases.
A second outbreak, now present in five provinces
Chad declared a new dengue epidemic on 3 October 2026, following an initial outbreak reported in 2023. As of 19 October, the health ministry reported more than 3,000 suspected cases, 250 confirmed cases and eight deaths. Cases had been reported in Wadi Fira, Ouaddaï, Sila, Batha and the city of N’Djamena, according to the tally presented by health authorities.
Figures published a few days earlier indicate the scale of the spread, but should not be confused with the tally as of 19 October. As of 16 October, data reported by Chad’s public media outlet ONAMA showed 2,929 suspected cases, 213 confirmed cases and seven deaths. The increase in the figures may reflect both the spread of the disease and changes in testing.
The capital already accounted for a major share of confirmed cases in mid-October: 173 confirmed cases, or 81% of the total announced at the time. The first reported outbreak was in Kounoungou camp, in Wadi Fira, in the east of the country. The disease was subsequently reported in other provinces, as well as in N’Djamena, where urban density and daily movement complicate surveillance.
Symptoms that can be mistaken for malaria
The first obstacle is clinical. Fever, fatigue, aches and headaches can suggest malaria, which is widespread in Chad, particularly during the rainy season. Patients may therefore self-medicate for malaria at a pharmacy before seeking medical advice. Severe dengue can lead to complications and requires appropriate care.
Caution is all the more important because some medicines used for pain or fever, particularly anti-inflammatory drugs, should be avoided if dengue is suspected. Health authorities recommend consulting a healthcare professional promptly. Dengue is transmitted by infected mosquitoes; removing standing water and limiting bites help reduce the risks, but do not replace diagnosis or treatment.
Diagnosis relies on laboratory tests. The source material, however, reported that testing kits were running low. This warning should be interpreted cautiously: the public data consulted do not make it possible to confirm the current scale of the shortage. But if tests are unavailable or delayed, the authorities have fewer means to distinguish dengue cases from other fevers, assess the spread of the virus and direct patients to care.
Treatment, a challenge beyond testing
The shortage of intensive care beds reported by health professionals highlights a structural difficulty: an epidemic outbreak can quickly put pressure on hospital capacity that is already limited. The effects are not the same everywhere. In N’Djamena, the concentration of cases can strain urban health centres. In remote provinces, travel to an adequately equipped facility and access to tests can delay treatment.
Families and patients also bear the cost of consultations and travel, while pharmacies often remain the first port of call. It is therefore essential to provide information without stigmatising self-medication: the problem also lies in securing rapid access to a reliable diagnosis and care close to home.
The outbreak comes as the country faces other health and humanitarian needs, particularly in the east, which has seen the arrival of people fleeing the conflict in Sudan. During the 2023 epidemic, the World Health Organization had already highlighted the limitations of surveillance, laboratory and treatment capacity in Chad. The new surge is a reminder that these capacities need to function continuously, between emergencies, and not only during response campaigns.
A response that must take borders and local conditions into account
The 2023 outbreak is a useful precedent, but the two episodes are not interchangeable. That first outbreak officially reported in Chad affected, among other areas, Ouaddaï, Sila, Wadi Fira and N’Djamena. As of 1 October 2023, the WHO had recorded 1,342 suspected cases and 41 confirmed cases. The new epidemic has a different geographical spread and different tallies; comparisons must therefore take account of the periods and counting methods.
The response is primarily national: surveillance, laboratory confirmation, care, information and mosquito control fall to the Chadian authorities. But Sudan’s proximity and population movements in the region make the sharing of alerts and cross-border health coordination useful. Chad is a member of the Economic and Monetary Community of Central Africa (CEMAC), a cooperation framework among several Central African countries; the sharing of health information there matters as much as national exchanges with partners working on the ground.
What happens next will depend on the ability to update consistent figures, secure testing supplies and direct patients to care quickly, in cities and provinces alike. The tallies in the coming weeks will show whether the geographical spread continues and whether confirmed cases rise in step with suspected cases. For Chadians, the immediate issue is practical: being able to recognise a fever that does not respond to usual treatments and access medical assessment without delay.



